Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Evans, M.
Right arrow Articles by Rees, A.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Pharmacological management of hyperlipidaemia

Marc Evans

University of Wales College of Medicine, Cardiff, marc.evans2{at}ntlworld.com

Aled Roberts

University Hospital of Wales, Cardiff

Alan Rees

University Hospital of Wales, Cardiff

Coronary heart disease (CHD) is a major cause of morbidity and mortality. Recent evidence supports the benefits of intensive low density lipoprotein-cholesterol (LDL-c) reduc-of intensive low density lipoprotein-cholesterol (LDL-c) reduction on CHD risk with various ongoing end point trials addressing the issue of optimal cholesterol reduction. Statins reduce LDL-c, and have been shown to reduce CHD event rates in both primary and secondary prevention trials. The magnitude of this effect is not fully accounted for by LDL-c reduction alone and may relate to effects on other lipid parameters.

Fibrates represent the best treatment for raising high density lipoprotein-cholesterol (HDL-c) and a variety of agents, which specifically target HDL-c, are under development.

New therapies being developed to meet the challenge of intensive cholesterol lowering include rosuvastatin, a potent statin, producing reductions in LDL-c of up to 69% and ezetimibe, a selective cholesterol absorption inhibitor, producing reductions in LDL-c of up to 25%.

This review summarises the evidence regarding dyslipidaemia and vascular risk and how advances in lipid-lowering therapy may be important in future management of hyperlipidaemia.

Key Words: cholesterol • coronary heart disease • statins.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 3, 204-210 (2003)
DOI: 10.1177/14746514030030030901
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?